Literature DB >> 18667502

Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Elena Gustchina1, Carole A Bewley, G Marius Clore.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) neutralization can be effected by several classes of inhibitors that target distinct regions of gp41 that are accessible in the prehairpin intermediate (PHI) state and block the formation of the six-helix bundle (6-HB) conformation of gp41. The N-heptad repeat (N-HR) of gp41 is the site of action of two classes of inhibitors. One class binds to the trimeric N-HR coiled coil, while the other, exemplified by the peptide N36(Mut(e,g)), disrupts the trimer and sequesters the PHI through the formation of heterotrimers. We recently reported a neutralizing Fab (Fab 3674), selected from a nonimmune phage library, that binds to the trimeric N-HR coiled coil through an epitope that remains exposed in the 6-HB and is also present in heterotrimers of the N-HR and N36(Mut(e,g)) peptide. Here we show that N36(Mut(e,g)) prolongs the temporal window during which the virus is susceptible to neutralization by the bivalent Fab 3674 and that bivalent Fab 3674 and N36(Mut(e,g)) neutralize HXB2 and SF162 strains of HIV-1, as well as isolates of diverse primary B and C HIV-1 strains, synergistically in a Env-pseudotyped virus neutralization assay. N36(Mut(e,g)) also rescues neutralizing activity of Fab 3674 against resistant virus strains and renders a series of related nonneutralizing Fabs neutralizing. Moreover, N36(Mut(e,g)) exhibits the same effects on the broadly neutralizing 2F5 and 4E10 monoclonal antibodies directed against the membrane-proximal extended region of gp41. The mechanistic implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667502      PMCID: PMC2566276          DOI: 10.1128/JVI.01050-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

2.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.

Authors:  K Salzwedel; E D Smith; B Dey; E A Berger
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.

Authors:  J M Louis; C A Bewley; G M Clore
Journal:  J Biol Chem       Date:  2001-06-19       Impact factor: 5.157

Review 5.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Authors:  E A Berger; P M Murphy; J M Farber
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

6.  HIV-1 inhibition by a peptide.

Authors:  S Jiang; K Lin; N Strick; A R Neurath
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

7.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

8.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

10.  Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.

Authors:  G B Melikyan; R M Markosyan; H Hemmati; M K Delmedico; D M Lambert; F S Cohen
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

View more
  23 in total

1.  Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Authors:  Cajetan Dogo-Isonagie; Son Lam; Elena Gustchina; Priyamvada Acharya; Yongping Yang; Syed Shahzad-ul-Hussan; G Marius Clore; Peter D Kwong; Carole A Bewley
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Authors:  Joshua S Klein; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Christopher P Foglesong; Anthony P West; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

3.  Short communication: Simultaneous substitutions of V38M and N43T-N44K in the gp41 heptad repeat 1 (HR1) disrupt HIV type 1 gPr160 endoproteolytic cleavage (*).

Authors:  V A Morozov; A V Morozov; S Lagaye
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

4.  Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis.

Authors:  Lautaro G Perez; Susan Zolla-Pazner; David C Montefiori
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

5.  Celebesides A-C and theopapuamides B-D, depsipeptides from an Indonesian sponge that inhibit HIV-1 entry.

Authors:  Alberto Plaza; Giuseppe Bifulco; Jessica L Keffer; John R Lloyd; Heather L Baker; Carole A Bewley
Journal:  J Org Chem       Date:  2009-01-16       Impact factor: 4.354

6.  Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.

Authors:  Dirk Roymans; Hendrik L De Bondt; Eric Arnoult; Peggy Geluykens; Tom Gevers; Marcia Van Ginderen; Nick Verheyen; Hidong Kim; Rudy Willebrords; Jean-François Bonfanti; Wouter Bruinzeel; Maxwell D Cummings; Herman van Vlijmen; Koen Andries
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

7.  Paltolides A--C, anabaenopeptin-type peptides from the palau sponge Theonella swinhoei.

Authors:  Alberto Plaza; Jessica L Keffer; John R Lloyd; Patrick L Colin; Carole A Bewley
Journal:  J Nat Prod       Date:  2010-03-26       Impact factor: 4.050

8.  Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

9.  Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.

Authors:  Elena Gustchina; John M Louis; Christian Frisch; Francisco Ylera; Annette Lechner; Carole A Bewley; G Marius Clore
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

10.  Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.

Authors:  Lautaro G Perez; Matthew R Costa; Christopher A Todd; Barton F Haynes; David C Montefiori
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.